Novo Holdings

We are pleased to expand our collaboration with European Energy to repower 17 onshore wind parks in Germany. By replacing the existing wind turbines with modern ones, we aim to triple their renewable energy capacity and contribute to more renewable energy use. Learn more: https://lnkd.in/d2Na3Jv4

We are looking for an Associate to join the Venture Investments team in supporting Partners and Principals in investment cases. The role as Associate provides exposure to venture capital, and the primary role will be to assess and conduct primary due diligence of new investment opportunities.

We are looking for a Senior Procurement Specialist to join the Finance & Operations team out of our Copenhagen Office. In the role as Senior Procurement Specialist, your primary tasks include the responsibility for procurement processes and systems, ensuring reliable, accurate and timely financial reporting to management.

Novo Holdings is pleased to announce that it has completed its previously announced acquisition of Catalent Pharma Solutions, a world-leading contract development and manufacturing organisation (CDMO). Catalent provides innovative solutions that enable pharmaceutical and biotech companies to accelerate the development and delivery of transformative therapies for patients around the globe. Through this partnership, Novo Holdings will leverage its deep experience in the life sciences sector to support Catalent’s growth as both companies advance their shared mission to help people around the world live better and healthier lives.   Learn more below

Novo Holdings has led a $100 million Series C financing in SiteOne Therapeutics, Inc., a biopharmaceutical company developing selective ion channel modulators as non-opioid treatments for acute pain and other conditions.   The funding will support the advancement of SiteOne’s portfolio, including its lead oral compound STC-004, which is currently in Phase 1 trials.   Learn more about SiteOne here: https://lnkd.in/e4cRmZcP   #ventureinvestments #investorsinlifesciences

We are looking for a Sustainability Professional to join Novo Holdings as part of our Sustainability and Impact team, where you will contribute to our ambitious journey as a leading responsible investor. As part of a collaborative team of three experienced professionals and a junior analyst, you will play a key role in shaping and advancing Novo Holdings’ sustainability efforts.

Novo Holdings is looking for an Associate or Senior Associate to join our Real Assets investment team in Copenhagen - a part of the Capital Investment division (CI). You will have a central role in the execution of the Novo Holdings’ Real Assets strategy with the aim of continuing the development of an investment portfolio with a balanced risk / return composition as well as strong responsible investment profile.”

Novo Holdings today announced its participation in a €80 million Series A financing round for Antag Therapeutics, a Danish biopharmaceutical company developing innovative therapies targeting obesity and cardiometabolic diseases.   Founded in 2017 and headquartered in Copenhagen, Denmark, Antag works to advance next-generation treatments for obesity, focusing on new therapeutic strategies to complement existing GLP-1 therapies.   The €80 million Series A round was led by Versant Ventures, with participation from SR One Capital Management, Dawn Biopharma, Pictet Group, Longview Ventures, and the Export and Investment Fund of Denmark (EIFO), alongside founding investor Novo Holdings.

Johan Hueffer, Senior Partner at Novo Holdings, spoke to CNBC today about our focus on innovation in planetary health, as evident by our recent investments in aquaculture leaders Benchmark Genetics and Stingray Marine Solutions AS.   Watch the interview here:

Novo Holdings participates in the oversubscribed $135 million series B financing in Adcendo, a biotech company focused on the development of first-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need.   The financing round was led by TCGX, with participation from new investors TPG, OrbiMed, VENROCK HEALTHCARE CAPITAL PARTNERS LP, Surveyor Capital, and Logos Capital, as well as all existing investors, including RA Capital Management, Novo Holdings, Pontifax Venture Capital, Dawn Biopharma, HealthCap, Gilde Healthcare and Ysios Capital.   Proceeds from the fundraise will be used to advance, broaden, and accelerate the development of Adcendo’s ADC pipeline.